Intrinsic value of XOMA - XOMA

Previous Close

$13.41

  Intrinsic Value

$0.17

stock screener

  Rating & Target

str. sell

-99%

Previous close

$13.41

 
Intrinsic value

$0.17

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of XOMA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  54
  55
  56
  58
  60
  62
  64
  66
  68
  71
  74
  77
  80
  84
  87
  91
  95
  99
  104
  109
  114
  119
  124
  130
  137
  143
  150
  157
  165
  173
Variable operating expenses, $m
  648
  663
  680
  699
  720
  744
  769
  796
  826
  857
  891
  928
  966
  1,007
  1,050
  1,096
  1,145
  1,197
  1,251
  1,309
  1,369
  1,433
  1,501
  1,572
  1,647
  1,725
  1,808
  1,896
  1,987
  2,084
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  648
  663
  680
  699
  720
  744
  769
  796
  826
  857
  891
  928
  966
  1,007
  1,050
  1,096
  1,145
  1,197
  1,251
  1,309
  1,369
  1,433
  1,501
  1,572
  1,647
  1,725
  1,808
  1,896
  1,987
  2,084
Operating income, $m
  -594
  -608
  -624
  -641
  -661
  -682
  -705
  -730
  -757
  -786
  -817
  -851
  -886
  -923
  -963
  -1,006
  -1,050
  -1,097
  -1,147
  -1,200
  -1,256
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,823
  -1,911
EBITDA, $m
  -594
  -608
  -623
  -641
  -660
  -682
  -705
  -730
  -757
  -786
  -817
  -850
  -886
  -923
  -963
  -1,005
  -1,050
  -1,097
  -1,147
  -1,200
  -1,255
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,822
  -1,911
Interest expense (income), $m
  0
  1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Earnings before tax, $m
  -595
  -607
  -623
  -640
  -660
  -681
  -704
  -729
  -756
  -786
  -817
  -850
  -885
  -923
  -963
  -1,005
  -1,050
  -1,097
  -1,147
  -1,200
  -1,255
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,822
  -1,911
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -595
  -607
  -623
  -640
  -660
  -681
  -704
  -729
  -756
  -786
  -817
  -850
  -885
  -923
  -963
  -1,005
  -1,050
  -1,097
  -1,147
  -1,200
  -1,255
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,822
  -1,911

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  9
  9
  9
  10
  10
  10
  11
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  28
  29
Adjusted assets (=assets-cash), $m
  9
  9
  9
  10
  10
  10
  11
  11
  11
  12
  12
  13
  13
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
  28
  29
Revenue / Adjusted assets
  6.000
  6.111
  6.222
  5.800
  6.000
  6.200
  5.818
  6.000
  6.182
  5.917
  6.167
  5.923
  6.154
  6.000
  5.800
  6.067
  5.938
  5.824
  6.118
  6.056
  6.000
  5.950
  5.905
  5.909
  5.957
  5.958
  6.000
  6.038
  5.893
  5.966
Average production assets, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
Working capital, $m
  -7
  -7
  -7
  -7
  -8
  -8
  -8
  -8
  -9
  -9
  -9
  -10
  -10
  -11
  -11
  -11
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -20
  -21
  -22
Total debt, $m
  -16
  -16
  -16
  -16
  -16
  -15
  -15
  -15
  -14
  -14
  -13
  -13
  -12
  -12
  -11
  -11
  -10
  -10
  -9
  -8
  -7
  -7
  -6
  -5
  -4
  -3
  -2
  -1
  0
  2
Total liabilities, $m
  8
  8
  9
  9
  9
  9
  10
  10
  10
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  26
Total equity, $m
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
Total liabilities and equity, $m
  9
  9
  10
  10
  10
  10
  11
  11
  11
  12
  12
  13
  13
  14
  14
  16
  16
  17
  18
  18
  19
  20
  21
  22
  23
  24
  26
  27
  28
  29
Debt-to-equity ratio
  -18.270
  -17.660
  -16.990
  -16.280
  -15.540
  -14.770
  -13.990
  -13.200
  -12.400
  -11.610
  -10.830
  -10.050
  -9.290
  -8.550
  -7.820
  -7.120
  -6.430
  -5.770
  -5.130
  -4.500
  -3.910
  -3.330
  -2.780
  -2.240
  -1.730
  -1.240
  -0.770
  -0.320
  0.110
  0.520
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -595
  -607
  -623
  -640
  -660
  -681
  -704
  -729
  -756
  -786
  -817
  -850
  -885
  -923
  -963
  -1,005
  -1,050
  -1,097
  -1,147
  -1,200
  -1,255
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,822
  -1,911
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Funds from operations, $m
  -595
  -607
  -623
  -640
  -660
  -681
  -704
  -729
  -756
  -785
  -817
  -850
  -885
  -923
  -962
  -1,005
  -1,049
  -1,097
  -1,147
  -1,199
  -1,255
  -1,314
  -1,376
  -1,441
  -1,509
  -1,582
  -1,658
  -1,738
  -1,822
  -1,911
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -595
  -607
  -622
  -640
  -659
  -681
  -704
  -729
  -756
  -785
  -816
  -849
  -885
  -922
  -962
  -1,004
  -1,049
  -1,096
  -1,146
  -1,199
  -1,254
  -1,313
  -1,375
  -1,440
  -1,509
  -1,581
  -1,657
  -1,737
  -1,821
  -1,910
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Free cash flow, $m
  -595
  -607
  -622
  -640
  -659
  -681
  -704
  -729
  -756
  -785
  -816
  -850
  -885
  -922
  -962
  -1,004
  -1,049
  -1,096
  -1,146
  -1,199
  -1,255
  -1,313
  -1,375
  -1,440
  -1,509
  -1,581
  -1,657
  -1,737
  -1,822
  -1,910
Issuance/(repayment) of debt, $m
  -31
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
Issuance/(repurchase) of shares, $m
  626
  607
  623
  640
  660
  681
  704
  729
  757
  786
  817
  850
  885
  923
  963
  1,005
  1,050
  1,097
  1,147
  1,200
  1,255
  1,314
  1,376
  1,441
  1,510
  1,582
  1,658
  1,738
  1,823
  1,911
Cash from financing (excl. dividends), $m  
  595
  607
  623
  640
  660
  681
  704
  729
  757
  786
  817
  850
  885
  924
  964
  1,006
  1,051
  1,098
  1,148
  1,201
  1,256
  1,315
  1,377
  1,442
  1,511
  1,583
  1,659
  1,739
  1,824
  1,912
Total cash flow (excl. dividends), $m
  -0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
Retained Cash Flow (-), $m
  -626
  -607
  -623
  -640
  -660
  -681
  -704
  -729
  -757
  -786
  -817
  -850
  -885
  -923
  -963
  -1,005
  -1,050
  -1,097
  -1,147
  -1,200
  -1,255
  -1,314
  -1,376
  -1,441
  -1,510
  -1,582
  -1,658
  -1,738
  -1,823
  -1,911
Prev. year cash balance distribution, $m
  36
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -590
  -607
  -622
  -640
  -659
  -680
  -704
  -729
  -756
  -785
  -816
  -849
  -884
  -922
  -962
  -1,004
  -1,049
  -1,096
  -1,146
  -1,198
  -1,254
  -1,313
  -1,374
  -1,440
  -1,508
  -1,580
  -1,656
  -1,736
  -1,820
  -1,909
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -566
  -555
  -542
  -527
  -511
  -494
  -475
  -456
  -434
  -411
  -387
  -362
  -336
  -309
  -282
  -255
  -228
  -202
  -176
  -152
  -130
  -109
  -90
  -73
  -59
  -46
  -36
  -27
  -20
  -14
Current shareholders' claim on cash, %
  50.0
  0.7
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

XOMA Corporation, a development stage biotechnology company, discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s product candidates include XOMA 358, a human negative allosteric modulating insulin receptor antibody is in phase 2 proof-of-concept study for treating congenital hyperinsulinism and post-meal hypoglycemia in post-bariatric surgery patients; XOMA 129, a potent fragment of a monoclonal antibody is under preclinical testing to treat patients with acute severe hypoglycemia; XOMA 213, a allosteric inhibitor for use in treating prolactinoma and anti-psychotic-induced hyperprolactinemia. It also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. The company has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

FINANCIAL RATIOS  of  XOMA (XOMA)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

XOMA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the XOMA stock intrinsic value calculation we used $52.69 million for the last fiscal year's total revenue generated by XOMA. The default revenue input number comes from 0001 income statement of XOMA. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our XOMA stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for XOMA is calculated based on our internal credit rating of XOMA, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of XOMA.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of XOMA stock the variable cost ratio is equal to 1205.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for XOMA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for XOMA.

Corporate tax rate of 27% is the nominal tax rate for XOMA. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the XOMA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for XOMA are equal to 1.1%.

Life of production assets of 1.8 years is the average useful life of capital assets used in XOMA operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for XOMA is equal to -12.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $5.786 million for XOMA - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 8.329 million for XOMA is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of XOMA at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 42.91 34.10  hold
NVO Novo Nordisk A 44.46 128.58  str.buy
EBS Emergent Bioso 66.31 3.72  str.sell
LLY Eli Lilly 109.81 67.15  sell

COMPANY NEWS

▶ Xoma: 3Q Earnings Snapshot   [10:52AM  Associated Press]
▶ XOMA Announces Proposed Rights Offering   [07:05AM  GlobeNewswire]
▶ Xoma: 2Q Earnings Snapshot   [05:08PM  Associated Press]
▶ XOMA Added to the Russell 2000® and Russell 3000® Indexes   [Jun-26-18 07:00AM  GlobeNewswire]
▶ XOMA to Present at the UBS Global Healthcare Conference   [May-15-18 07:00AM  GlobeNewswire]
▶ Xoma: 1Q Earnings Snapshot   [May-09-18 06:11PM  Associated Press]
▶ Xoma reports 4Q loss   [Mar-07-18 05:46PM  Associated Press]
▶ East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs   [Jan-26-18 03:54PM  American City Business Journals]
▶ 3 Pharma and Biotech Stocks to Watch Out for in 2018   [Jan-23-18 11:30AM  InvestorPlace]
▶ It was a banner year for stocks, but not everyone shared in the wealth.   [Jan-08-18 03:00PM  American City Business Journals]
▶ 4 Biotech Stocks to Watch in the New Year   [Jan-05-18 04:25PM  Zacks]
▶ 3 Best Healthcare Stocks of 2017   [06:34AM  Motley Fool]
▶ 5 of the Best-Performing Biotech Stocks of 2017   [Dec-28-17 08:07AM  Zacks]
▶ ETFs with exposure to XOMA Corp. : December 27, 2017   [Dec-27-17 12:05PM  Capital Cube]
▶ 3 Buy-Ranked Biotech Stocks That Soared in 2017   [Dec-20-17 03:44PM  Zacks]
▶ The 3 Best Biotech Stocks of 2017   [Dec-17-17 09:09AM  Motley Fool]
▶ ETFs with exposure to XOMA Corp. : December 11, 2017   [Dec-11-17 02:17PM  Capital Cube]
▶ ETFs with exposure to XOMA Corp. : November 30, 2017   [Nov-30-17 02:40PM  Capital Cube]
▶ Xoma: A Lower Risk Way Of Investing In Biotech   [Nov-10-17 05:14PM  Forbes]
▶ Xoma beats 3Q profit forecasts   [Nov-06-17 05:28PM  Associated Press]
▶ ETFs with exposure to XOMA Corp. : September 7, 2017   [Sep-07-17 02:17PM  Capital Cube]
▶ ETFs with exposure to XOMA Corp. : August 25, 2017   [Aug-25-17 05:56PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.